RAPIDNeural — Nerve Repair + Remyelination Platform

RAPIDNEURAL

Nerves that reconnect. A scaffold that actively guides axon growth past the gap limit every current conduit accepts. Fucoidan-functionalised sargassum scaffold presenting NGF on the surface — neurite outgrowth without exogenous growth factor in solution, gaps beyond 25–30mm, active remyelination via PI3K/AKT/mTOR. And the same mechanism that repairs a blast-damaged peripheral nerve is the mechanism that fails in MS, Parkinson's, and Alzheimer's disease.

Combat — peripheral nerve repair Neurodegeneration — remyelination platform

30mm+ Gap capability

200M+ Neurological patients

ZERO Approved remyelination therapies

£0 Feedstock cost

Request Briefing Neurological indications RAPIDHealth Platform

THE 25mm CEILING

Every approved nerve conduit on the market has an accepted functional gap limit of 25–30mm. Beyond that, functional recovery fails. Blast injuries to peripheral nerves routinely exceed this limit. The market has accepted the ceiling. RAPIDNeural doesn't.

Current approved conduit limit

25–30mm

Beyond this gap length, approved hollow tube conduits cannot bridge the distance with functional axon regeneration. No exogenous NGF in solution. No active guidance. Passive structure only. Blast injuries regularly create gaps that exceed this by 2–4×.

Passive tubes only. Current conduits provide a channel. They do not guide, promote, or accelerate axon growth. The nerve is expected to bridge the gap unassisted.

No NGF presentation. Nerve growth factor is essential for neurite extension. Current conduits require exogenous NGF in solution — unstable, dose-dependent, and difficult to deliver uniformly across the gap.

No remyelination activity. Axon regeneration across a gap is necessary but not sufficient. Without remyelination — Schwann cell recruitment and myelin sheath formation — signal conduction fails. No approved conduit promotes active remyelination.

No antimicrobial protection. Peripheral nerve injuries in combat occur in contaminated environments. Conduit infection destroys the repair. Current products have no intrinsic antimicrobial mechanism.

RAPIDNeural

Surface-presented NGF. Fucoidan presents NGF on the scaffold surface — not in solution. Stable, orientated, physiological concentration. Neurite outgrowth without exogenous NGF injection. The guidance cue is embedded in the material.

30mm+ gap capability. Active guidance via surface-presented NGF enables axon extension across gaps that exceed the passive conduit limit. Blast nerve injuries — femoral, sciatic, radial, ulnar — become reconstructable.

Active remyelination. Fucoidan promotes OPC (oligodendrocyte precursor cell) differentiation into myelinating oligodendrocytes via PI3K/AKT/mTOR. The scaffold doesn't just bridge the gap — it actively drives the remyelination required for functional signal conduction.

Intrinsic antimicrobial + glial scar reduction. Phlorotannin anti-biofilm and holobiont MRSA activity protects the repair site. Fucoidan reduces glial scar formation — the fibrotic barrier to axon extension that passive conduits cannot address.

HOW IT WORKS

RAPIDNeural operates through two parallel biological programmes — axon guidance and remyelination — running simultaneously from the moment of implantation. Both depend on the same non-thermally-processed native fucoidan sulphation. Both fail with thermally extracted fucoidan.

Scaffold implantation

Fucoidan-functionalised sargassum matrix

Non-thermally-processed sargassum scaffold bridges the nerve gap. Native fucoidan sulphation is intact — the specific molecular geometry required for NGF binding is preserved. Thermally extracted fucoidan loses this. No prior art product achieves NGF surface presentation from a sargassum-derived scaffold.

NGF surface presentation

Fucoidan–NGF binding via native sulphation

NGF binds to the fucoidan sulphate groups on the scaffold surface. Presented in orientated, stable form at physiological concentration — the neurotrophic signal that axons follow. No exogenous NGF injected into solution. The guidance cue is the scaffold.

Directed neurite outgrowth

Axon extension along NGF gradient

Axons follow the surface-presented NGF gradient across the gap. Glial scar formation — the fibrotic barrier that halts axon extension in passive conduits — is reduced by fucoidan's anti-inflammatory activity. Axons reach the distal stump.

OPC recruitment and differentiation

PI3K/AKT/mTOR — OPC → oligodendrocyte

Fucoidan activates PI3K/AKT/mTOR signalling in oligodendrocyte precursor cells — driving their differentiation into myelinating oligodendrocytes. Active remyelination. Not passive. The repaired axon is wrapped in functional myelin. Signal conduction is restored, not just anatomical continuity.

Why surface presentation matters

NGF in solution degrades rapidly, distributes non-uniformly, and cannot establish a directional gradient across a 30mm+ gap. Surface-presented NGF is stable, orientated, and creates a consistent gradient from proximal to distal stump. The scaffold is the delivery system. No injection. No dose management. No degradation kinetics to model.

Why native sulphation is the inventive step

Fucoidan's NGF-binding capacity is a function of its sulphation pattern — the specific arrangement of sulphate groups on the polysaccharide backbone. Thermal extraction disrupts this pattern. Commercial fucoidan cannot bind NGF in the orientated manner required for surface presentation. Non-thermal processing of Bio-Farm sargassum is the only available route to a manufacturable scaffold with this property.

The PI3K/AKT/mTOR pathway — why it matters beyond combat

OPC differentiation into myelinating oligodendrocytes via PI3K/AKT/mTOR is not unique to peripheral nerve repair. It is the same pathway whose failure underlies the progressive demyelination in MS, Parkinson's, and Alzheimer's disease. The same fucoidan formulation that remyelinates a blast-injured peripheral nerve is the candidate mechanism for neurodegenerative disease therapy. Different delivery. Same chemistry.

200 MILLION PATIENTS. ZERO APPROVED REMYELINATION THERAPIES.

Combat is the entry point. Clinical validation, IP protection, and regulatory precedent established through battlefield nerve repair. The global commercial scale is neurodegeneration. The PI3K/AKT/mTOR remyelination mechanism active in RAPIDNeural is the same pathway whose failure defines three of the most prevalent and commercially significant disease categories in medicine — none of which have an approved remyelination therapy.

2.8M

Multiple Sclerosis

OPC → oligodendrocyte failure via PI3K/AKT/mTOR disruption

MS is defined by progressive immune-mediated demyelination and the progressive failure of remyelination. OPCs are present in lesions — they fail to differentiate into myelinating oligodendrocytes. RAPIDNeural's fucoidan scaffold activates exactly this differentiation step via PI3K/AKT/mTOR. The mechanism is the same. The delivery format changes — scaffold application or injectable fucoidan formulation depending on lesion location and accessibility.

Current gap: No approved therapy promotes active remyelination in MS. Disease-modifying therapies reduce relapse rate — none restore lost myelin.

10M

Parkinson's Disease

PI3K/AKT/mTOR dysregulation in dopaminergic neuron degeneration

Dopaminergic neuron degeneration in Parkinson's proceeds through PI3K/AKT/mTOR pathway disruption — the same pathway RAPIDNeural targets for OPC differentiation. The neuroprotective and neuroregenerative properties of native-sulphation fucoidan are under investigation for dopaminergic neuron protection. Fucoidan's anti-inflammatory activity via NF-κB suppression also addresses neuroinflammation central to Parkinson's pathophysiology.

Current gap: Levodopa manages symptoms. Nothing halts or reverses dopaminergic neuron loss. No remyelination or neuroprotection therapy approved.

55M

Alzheimer's Disease

Neurodegeneration, amyloid cascade, myelin loss, OPC failure

Alzheimer's involves progressive neurodegeneration with substantial myelin loss and failure of endogenous remyelination mechanisms. Fucoidan has demonstrated inhibition of beta-amyloid aggregation and tau phosphorylation in research contexts. The native sulphation preserved by non-thermal processing is required for these neuroactive properties — absent in all commercially extracted fucoidan. RAPIDNeural's formulation is the only manufacturable candidate that retains this activity.

Current gap: Two amyloid-targeting therapies approved — neither remyelinates, neither halts progression in all patients. No myelin-restoring therapy exists.

THE ENTRY POINT

Peripheral nerve injuries are among the most debilitating consequences of blast trauma — functional loss of limb, chronic pain, and loss of sensation. Combat is the validation pathway. The indications below establish the clinical evidence base that opens the neurological market.

Blast Nerve Transection

Combat — primary indication

IED and fragmentation injuries transect peripheral nerves — femoral, sciatic, radial, ulnar — with gap lengths that routinely exceed the 25–30mm passive conduit limit. RAPIDNeural's NGF surface presentation enables functional repair of gaps that no current conduit can address.

Previous standard: Autologous nerve graft — donor site sacrifice, limited length, variable outcome

Traumatic Nerve Crush

Combat + civilian — major trauma

Crush injuries damage the nerve without transection — axon disruption within an intact sheath. Glial scar formation blocks spontaneous regeneration. Fucoidan's anti-inflammatory activity reduces scar formation. NGF surface presentation reactivates arrested axon growth. Active remyelination restores conduction.

Previous standard: Observation and physiotherapy — dependent on incomplete spontaneous recovery

Contaminated Nerve Wounds

Combat — forward deployed

Blast and penetrating wounds are universally contaminated. Nerve repair conduit infection destroys the reconstruction. Intrinsic phlorotannin anti-biofilm and holobiont MRSA-active antimicrobial activity protects the repair site without systemic antibiotics — the only conduit with this property.

Previous standard: Delayed repair after wound stabilisation — nerve gap lengthens with retraction during delay

PRODUCT SPECIFICATION

Parameter	Specification
Scaffold base	Fucoidan-functionalised sargassum matrix, non-thermal processing
NGF delivery	Surface presentation via native fucoidan sulphation — no exogenous NGF in solution
Gap capability	30mm+ — exceeds all current approved conduit limits
Remyelination	Active — OPC → oligodendrocyte via PI3K/AKT/mTOR
Glial scar	Reduced — fucoidan anti-inflammatory activity
Antimicrobial	MRSA-active, non-antibiotic — phlorotannins + holobiont
Feedstock	Arsenic-remediated pelagic sargassum, Bio-Farm supply chain
Cold chain	Not required — ambient stable
Donor material	None — no autologous nerve graft required
Arsenic compliance	ICH Q3D pharmaceutical grade
Regulatory pathway	Class III Medical Device (peripheral nerve) / Phase I IND (neurological)
Current TRL	2–3 — pre-patent, pre-clinical development

Intellectual property

RAPIDNeural

Patent application in preparation

Fucoidan-Functionalised Sargassum Scaffold for Peripheral Nerve Repair and Remyelination — Non-Thermal Processing as Enabling Innovation

Fucoidan-functionalised scaffold with surface-presented NGF via native sulphation — peripheral nerve gap bridging without exogenous NGF in solution

Non-thermal processing as the enabling step — native sulphation preservation is the inventive distinction from all prior art fucoidan nerve conduit products

Active remyelination via PI3K/AKT/mTOR — OPC differentiation claim covering peripheral nerve and central nervous system applications

Neurological indication claims — MS, Parkinson's, Alzheimer's — remyelination and neuroprotection via the same fucoidan formulation in alternative delivery formats

Glial scar reduction and contaminated nerve wound repair — anti-inflammatory and antimicrobial activity of the four-component sargassum chemistry

Haemostatic wound care

RAPIDGel

Wound seal + antimicrobial

View →

Dermal regeneration

RAPIDSkin

Skin without donors

View →

Osseous reconstruction

RAPIDBone

Bone without rhBMP

View →

Nerve repair + remyelination

RAPIDNeural

You are here

Multi-tissue, one operation

RAPIDSystem

The integrated platform

View →

Neurology · Neuroscience · Defence procurement · NHS · Biotech investment

REQUEST A BRIEFING

Full pre-patent technical documentation, mechanism evidence base, and neurological indication development roadmap available under NDA. Two markets. One chemistry. Combat validates. Neurodegeneration scales.

Request Briefing RAPIDHealth Platform